Table 3 Inter-treatment (combined vs deferiprone and combined vs deferoxamine) prospective comparisons in patients with basal global heart T2* < 20 ms
P | Deferiprone group (n = 9) | Combined group (n = 26) | Deferoxamine group (n=21) | P | |
|---|---|---|---|---|---|
Mean Diff Serum Ferritin (ng/ml) | 0.005 | −112 ± 241 | −679 ± 835 | −133 ± 575 | 0.017 |
Mean Diff Global Heart T2* (ms) | 0.107 | +8.8 ± 8.6 | +4.5 ± 6.1 | +3.7 ± 5.5 | 0.644 |
Mean Diff MRI CIC (mg/g dry w) | 0.540 | −0.36 ± 1.78 | −0.75 ± 1.67 | −0.35 ± 0.55 | 0.255 |
Mean Diff N seg. With T2* < 20 ms | 0.100 | −6.0 ± 5.6 | −2.4 ± 3.8 | −2.9 ± 3.7 | 0.638 |
Mean Diff Mid-Septum T2* (ms) | 0.295 | +6.1 ± 7.4 | +3.3 ± 7.1 | 2.9 ± 5.6 | 0.841 |
Mean Diff LV EF (%) | 0.181 | +5.0 ± 6.4 | +1.5 ± 6.7 | +2.0 ± 6.5 | 0.802 |
Mean DIFF LV EDVI (ml/m2) | 0.796 | −6.0 ± 12.3 | −4.6 ± 13.9 | −7.7 ± 11.6 | 0.432 |
Mean Diff RV EF (%) | 0.137 | +6.8 ± 3.7 | +3.2 ± 6.7 | +0.2 ± 8.8 | 0.187 |
Mean Diff RV EDVI (ml/m2) | 0.909 | −6.9 ± 11.7 | −7.5 ± 12.5 | −5.8 ± 17.1 | 0.702 |
Mean Diff Liver T2* (ms) | 0.010 | +2.0 ± 7.5 | +5.7 ± 6.9 | +2.9 ± 4.2 | 0.026 |
Mean Diff MRI LIC (mg/g/dw) | 0.009 | −0.1 ± 3.2 | −4.9 ± 6.1 | −1.7 ± 2.8 | 0.024 |